EU/3/18/2096: Orphan designation for the treatment of anti-glomerular basement membrane disease



On 19 November 2018, orphan designation (EU/3/18/2096) was granted by the European Commission to Hansa Medical AB, Sweden, for imlifidase for the treatment of anti-glomerular basement membrane disease.

In February 2019, Hansa Medical AB changed name to Hansa Biopharma AB.

Key facts

Active substance
Intended use
Treatment of anti-glomerular basement membrane disease
Orphan designation status
EU designation number
Date of designation

Hansa Biopharma AB
Scheelevägen 22
P.O. Box 785
Tel. +46 4616 5670

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating